Janssen To Change Name Of Reminyl Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Janssen agreed to change the brand name for galantamine products due to continued confusion with Aventis' Amaryl, which has resulted in medication errors. The company will submit new proposed names to FDA for review.
You may also be interested in...
Reminyl Gets New Name – Razadyne – Ahead Of ER Launch
The name change for the Alzheimer's product follows reports of medication errors with Sanofi-Aventis' diabetes product Amaryl. J&J agreed to change the name prior to launching the extended-release version of galantamine, which will be available in pharmacies in May.
Reminyl Gets New Name – Razadyne – Ahead Of ER Launch
The name change for the Alzheimer's product follows reports of medication errors with Sanofi-Aventis' diabetes product Amaryl. J&J agreed to change the name prior to launching the extended-release version of galantamine, which will be available in pharmacies in May.
Medication Errors, Drug Packaging On USP's Agenda
The U.S. Pharmacopeia will hear comments and vote on 12 proposed resolutions at its convention in Washington, D.C. March 9-13. One proposal calls for "further consideration" of drug packaging for increasingly complex ingredients and dosage forms.